Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

KRYS stock hub

Krystal Biotech, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KRYSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

KRYS

In the news

Latest news · KRYS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E35.2

P25 12.3P50 18.4P75 33.1

Trailing P/E40.9

P25 14.9P50 23.2P75 38.5

ROE19.9

P25 -105.6P50 -46.5P75 -3.1

ROIC41.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KRYS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

241

Groups with data

Currency

USD

Showing 241 of 241 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001711279
Company name	Krystal Biotech, Inc.
Country	United States
Country code	US
Cusip	501147102
Employees	295
Employees Change	20%
Employees Change Percent	7.27
Enterprise value	$8B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2017-09-20
Isin	US5011471027
Last refreshed	2026-05-10
Market cap	$9B
Market cap category	Mid-Cap
Price	$306
Price currency	USD
Rev Per Employee	1,414,589.83x
Sector	Healthcare
Sic	2836
Symbol	KRYS
Website	https://www.krystalbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.5%
EV Earnings	35.57x
EV Sales Forward	14.03x
EV/EBIT	44.78x
EV/EBITDA	44.35x
EV/FCF	33.72x
EV/Sales	19.18x
FCF yield	2.63%
Forward P/E	35.22x
P/B ratio	7.05x
P/E ratio	40.94x
P/S ratio	21.6x
PE Ratio3 Y	77.12x
PEG ratio	0.63x
PS Forward	15.8x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	42.83%
EBITDA Margin	43.25%
FCF margin	56.88%
Gross margin	94.17%
Gross Profit	$393M
Gross Profit Growth	26.44%
Gross Profit Growth Q	32.32%
Net Income	$225M
Net Income Growth	81.53%
Net Income Growth Q	56.53%
Net Income Growth Quarters	6%
Net Income Growth Years	3%
Pretax Margin	49.68%
Profit Margin	53.92%
Profit Per Employee	$762,814
Profitable Years	3
ROA	9.04
Roa5y	-3.12
ROCE	13.86
ROE	19.9
Roe5y	-1.97
ROIC	41.4
Roic5y	-23.48

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	123.6%
Cagr3y	53.66%
Cagr5y	34%
EPS Growth	79.7
EPS Growth Q	52.5
EPS Growth Quarters	6
EPS Growth Years	3
FCF Growth	83.56%
FCF Growth Q	195.72%
OCF Growth	80.71%
OCF Growth Q	159.56%
Revenue Growth	25.15x
Revenue Growth Q	31.95x
Revenue Growth Quarters	7x
Revenue Growth Years	2x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.34
Assets	$1.4B
Cash	$823.4M
Current Assets	$1B
Current Liabilities	$107.8M
Debt	$9.1M
Debt EBITDA	$0.05
Debt Equity	$0.01
Debt FCF	$0.04
Equity	$1.3B
Liabilities	$120.2M
Long Term Assets	$377.2M
Long Term Liabilities	$12.4M
Net Cash	$1B
Net Cash By Market Cap	$11.18
Net Cash Growth	33.36%
Net Debt EBITDA	$-5.58
Net Debt Equity	$-0.79
Net Debt FCF	$-4.25
Tangible Book Value	$1.3B
Tangible Book Value Per Share	$43.37
WACC	6.96

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.46
Inventory Turnover	0.67
Net Working Capital	$90.3M
Quick ratio	8.82
Working Capital	$911.9M
Working Capital Turnover	$0.52

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.75%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	123.47%
200-day SMA	221.3
3Y total return	262.9%
50-day SMA	264
50-day SMA vs 200-day SMA	50over200
5Y total return	331.92%
All Time High	306.1
All Time High Change	-0.13%
All Time High Date	2026-05-08
All Time Low	8.03
All Time Low Change	3,707.1%
All Time Low Date	2017-12-19
ATR	12.48
Beta	0.49
Beta1y	0.56
Beta2y	0.71
Ch YTD	24
High	306.1
High52	306.1
High52 Date	2026-05-08
High52ch	-0.13%
Low	292
Low52	122.8
Low52 Date	2025-05-23
Low52ch	148.95%
Ma50ch	15.78%
Premarket Change Percent	0.99
Premarket Price	$300
Premarket Volume	1,947
Price vs 200-day SMA	38.15%
RSI	71.66
RSI Monthly	72.18
RSI Weekly	69.75
Sharpe ratio	2.15x
Sortino ratio	3.49
Total Return	-0.75%
Tr YTD	24
Tr1m	15.8%
Tr1w	14.91%
Tr3m	12.09%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	12
Analyst Count Top	3
Analyst Price Target Top	$326
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$1.43
Earnings EPS Estimate Growth	19.17
Earnings Revenue Estimate	112,135,680x
Earnings Revenue Estimate Growth	27.16x
Operating Income	$178.7M
Operating Income Growth	33.7
Operating Income Growth Q	48.1
Operating margin	42.83
Price target	$298
Price Target Change	$-2.37
Price Target Change Top	$6.64

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	23,369,649%
Float Percent	79.27%
Shares Insiders	10.42%
Shares Institutions	87.7%
Shares Out	29,479,756
Shares Qo Q	0.85%
Shares Yo Y	0.75%
Short Float	12.46%
Short Ratio	10.01
Short Shares	9.88

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$182.7M
Average Volume	302,940.7x
Bv Per Share	43.37
CAPEX	$-12.9M
Ch1m	15.8
Ch1w	14.91
Ch1y	123.5
Ch3m	12.09
Ch3y	262.9
Ch5y	331.9
Ch6m	54.45
Change	3.04%
Change From Open	2.93
Close	296.7
Days Gap	0.1
Depreciation Amortization	1,736,000
Dollar Volume	143,861,011.8
Earnings Date	2026-05-04
Earnings Time	bmo
EBIT	$178.7M
EBITDA	$180.5M
EPS	$7.47
F Score	5
FCF	$237.4M
FCF EV Yield	2.97x
FCF Per Share	$8.05
Financing CF	10,712,000
Fiscal Year End	December
Founded	2,015
Graham Number	85.36551
Graham Upside	-72.08
Income Tax	$-17.7M
Investing CF	-67,231,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-04
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-17
Ma150	244.5
Ma150ch	25.05%
Ma20	275.2
Ma20ch	11.11%
Net CF	192,543,000
Next Earnings Date	2026-08-03
Open	297
Optionable	Yes
P FCF Ratio	37.97
P OCF Ratio	36.01
Position In Range	97.23
Post Close	305.7
Postmarket Change Percent	3.77
Postmarket Price	$317
Ppne	160,617,000
Pre Close	296.7
Price Date	2026-05-08
Price EBITDA	$49.94
Ptbv Ratio	7.06
Relative Volume	1.55x
Revenue	417,304,000x
SBC By Revenue	13.09x
Share Based Comp	54,645,000
Tax By Revenue	-4.24x
Tr6m	54.45%
Us State	Pennsylvania
Volume	470,580
Z Score	29.48

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KRYS pay a dividend?

Capital-return profile for this ticker.

Performance

KRYS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KRYS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+87.7%

Float: +79.3% of shares outstanding

Insider ownership

+10.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

KRYS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

71.7

Above 70: short-term overbought

Price vs 200-day MA

+38.1%

50/200-day relationship not available

Beta (5Y)

0.49

Less volatile than the market

Sharpe ratio

2.15

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KRYS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current KRYS stock rating?

Krystal Biotech, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KRYS analysis?

The full report lives at /stocks/KRYS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for KRYS?

The latest report frames KRYS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the KRYS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.